Metastatic Colorectal Cancer

BEACON CRC Safety Lead-in Study suggests safety and efficacy of triplet combination therapy for treatment of metastatic colorectal cancer

1. BEACON CRC is a multicenter, randomized, phase 3 clinical trial evaluating the triplet combination of binimetinib (BINI, a MEK inhibitor) + encorafenib (ENCO, a BRAF inhibitor) + cetuximab (CETUX, an EGFR antibody) for the treatment of metastatic colorectal cancer. 2. Preliminary analysis of the Safety Lead-in Study for the BEACON CRC reveals that the []

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Regorafenib prolongs survival in face of GI cancers

Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.

Patient preference doesn't affect chemo in advanced CRC

Patient preference doesn't affect chemo in advanced CRC

Most advanced colorectal cancer patients receive chemotherapy even if they doubt the benefits.

FDA Update - July/August 2012

News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik

Metastatic Colorectal Cancer and KRAS Gene Testing

Metastatic Colorectal Cancer and KRAS Gene Testing

Patients with metastatic colorectal cancer can use this fact sheet to learn more about personalized medicine and KRAS gene testing.

Cancer of the appendix differs from colorectal cancer after all

Gene expression profiling has demonstrated that appendiceal cancer is quite distinct from colorectal cancer and may require different treatment.

Two approaches recommended to reduce oxaliplatin toxicity during colorectal therapy


A review addresses the need to balance the effectiveness of oxaliplatin against its dose-limiting complication of neurotoxicity.

Experimental agent slows progression of colorectal cancer


The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.

LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication

The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.

Case Study: Downstaging liver metastases in colorectal cancer

A 35-year-old woman presents with a one-day history of lower-right abdominal pain, setting the stage for chemotherapy for metastatic colorectal cancer

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs